What is Resolve Therapeutics?
Resolve Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of innovative treatments for inflammatory conditions. The company's core technology centers on nuclease Fc fusion proteins, which are engineered to digest harmful RNA and DNA that contribute to disease progression. By targeting the source of inflammation, Resolve Therapeutics aims to provide transformative solutions for patients suffering from systemic lupus erythematosus, Sjogren's syndrome, and other complex autoimmune disorders. The company's market position is defined by its scientific rigor and its ability to translate novel molecular biology into viable clinical assets, positioning it as a key player in the evolving landscape of precision medicine.
How much funding has Resolve Therapeutics raised?
Resolve Therapeutics has raised a total of $7.8M across 2 funding rounds:
Series A
$2M
Series B
$5.8M
Series A (2011): $2M with participation from Easton Capital and New Science Ventures
Series B (2012): $5.8M led by Easton Capital, Washington Research Foundation, and New Science Ventures
Key Investors in Resolve Therapeutics
Easton Capital
Easton Capital Investment Group is a private equity firm managing institutional capital with a focus on strategic investments in growth-oriented companies, often participating in both initial and follow-on funding rounds.
New Science Ventures
New Science Ventures is a venture capital firm specializing in early and late-stage life sciences and information technology, prioritizing companies that utilize novel scientific approaches to solve significant unmet needs.
Washington Research Foundation
The Washington Research Foundation supports the advancement of research and innovation, often acting as a catalyst for academic-led scientific breakthroughs and early-stage commercialization efforts.
What's next for Resolve Therapeutics?
Looking ahead, Resolve Therapeutics is poised to leverage its recent capital influx to broaden the scope of its clinical investigations. The strategic focus will likely remain on optimizing the efficacy of RSLV-132 and RSLV-145 while exploring new therapeutic indications where nucleic acid accumulation drives pathology. As the company matures, the emphasis will shift toward scaling its operational capabilities and potentially pursuing strategic partnerships to facilitate late-stage development and commercialization. With a robust scientific foundation and continued support from institutional investors, Resolve Therapeutics is well-positioned to address significant unmet medical needs and deliver long-term value in the competitive biopharmaceutical market.
See full Resolve Therapeutics company page
